Login
$PTHS
$7.15 +$0.00 (0.0%) After hours

$PTHS 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025

30 Oct 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +6 more

Form of Amended and Restated Limited Liability Company Agreement of the Surviving Company

01 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(a) The purpose of this 2026 Equity Incentive Plan (the “Plan”) is to encourage key service providers of Pelthos Therapeutics Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by ...

13 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

13 Aug 2026 8-K: Non-Reliance on Previously Issued Financial Statements

On August 12, 2026, the audit committee of our board of directors (the “Audit Committee”), in consultation with management, concluded that because of a misapplication of Accounting Standards Codification (“ASC”) 820, Fair Value Measureme...

28 May 2026 8-K: Regulation FD Disclosure

1 Jefferies Global Healthcare Conference J U N E 4 , 2 0 2 6 Exhibit 99.2

21 May 2026 8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation

THIS SEPARATION AND RELEASE AGREEMENT (this “Agreement”) is made by and between Pelthos Therapeutics Inc. (the “Company”) and Francis Knuettel II (“Employee”). Each of the Company and Employee may be referred to herein as a “Party,” or c...

14 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026

14 Apr 2026 8-K: Regulation FD Disclosure

2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Wo...

10 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Executive Employment Agreement (this “Agreement”) is made as of April 10, 2026, by and between Pelthos Therapeutics, Inc., a Nevada Corporation, (the “Company”), and John M. Gay (the “Executive”).

19 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including lic...

13 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

The Lender, Collateral Agent and Co-Borrowers hereby agree as follows:

12 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Wo...

02 Jan 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Asset Purchase Agreement (this “Agreement”) is entered into as of this December 23, 2025, by and between Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation with a principal office at Level 17, 40 City Rd, Southbank, Victor...

23 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Seasoned executive brings four decades of finance, capital markets, and life sciences experience

17 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 17, 2025, Pelthos Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the three proposals that were voted on at the Annual Meeting and the stockholder vot...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Conference call scheduled for November 13, 2025 at 8:00am ET

07 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as November 6, 2025, is by and among Pelthos Therapeutics Inc., a Nevada corporation with offices located at 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 (the “Company”...

14 Oct 2025 8-K: Regulation FD Disclosure

Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Word...

03 Sep 2025 8-K: Regulation FD Disclosure

Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Word...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support